The anti-CD16/CD30 BiKE, which targets the lymphoma antigen CD30, was enrolled in a clinical trial on relapsed/refractory Hodgkin’s lymphoma (HL) patients, which showed a high overall response rate in patients with CD30+ T-cell malignancies (NCT03192202). Here, TNFRSF8 is linked to Hodgkins lymphoma.